GlassScriptPhysician profile
Isabel Warrick
NPI 1295311447
$2,225.16
in general payments reported to CMS, 2019-2025
22 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.47 · 2022: $396 · 2023: $608 · 2024: $754 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.79 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $471.42 | 2022-2025 | Otezla, Otezla |
| Abbvie INC. | $196.08 | 2022-2025 | |
| Medtronic, INC. | $175.00 | 2022 | |
| Dermavant Sciences, INC. | $159.50 | 2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $152.19 | 2022-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $127.47 | 2022-2025 | Nemluvio |
| Biofrontera INC. | $124.83 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Janssen Biotech, INC. | $106.42 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $105.29 | 2022-2023 | |
| Genzyme Corporation | $90.12 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $81.95 | 2021-2024 | Blu-U |
| Regeneron Healthcare Solutions, INC. | $78.83 | 2024-2025 | Dupixent |
| Pfizer INC. | $76.09 | 2022-2024 | |
| Merz North America, INC. | $54.70 | 2023 | Xeomin |
| Incyte Corporation | $49.97 | 2022-2023 | Opzelura |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $49.86 | 2024-2025 | Taltz, Ebglyss |
| Verrica Pharmaceuticals INC. | $23.95 | 2024 | Ycanth |
| Arcutis Biotherapeutics, INC. | $22.43 | 2025 | Zoryve |
| Kerecis Limited | $22.18 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Convatec INC. | $21.61 | 2024 | |
| Organogenesis INC. | $20.09 | 2025 | Puraply Wound Matrix |
| Revance Therapeutics, INC. | $15.18 | 2024 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Warrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.